What makes lenacapavir a first-in-class PrEP candidate
Lenacapavir is a capsid inhibitor — a mechanistic class that targets the HIV-1 capsid protein at multiple stages of the viral replication cycle, distinguishing it from every existing daily oral PrEP agent. Developed by Gilead Sciences, the compound is covered by a family of patents classified under WIPO IPC code A61K31/541 (pharmaceutical preparations containing nitrogen-bearing heterocyclic compounds) and A61P31/18 (antivirals for HIV/AIDS), with capsid inhibitor compound patents additionally carrying C07D487/04.
The clinical significance of that mechanism lies in its pharmacokinetic durability. Because the compound achieves sustained tissue concentrations, Gilead’s patent filings describe a PrEP regimen requiring only two subcutaneous injections per year — a twice-yearly schedule that has no precedent among approved HIV prevention medicines. The core dosing method, as described in Gilead patent US20220110943A1 (filed October 2021), involves an oral loading dose on day 1 and optionally day 2, followed by subcutaneous injections every 26 weeks.
Lenacapavir is a first-in-class HIV capsid inhibitor developed by Gilead Sciences. For pre-exposure prophylaxis, it is administered as a subcutaneous injection every 26 weeks (biannually), preceded by an oral loading dose on day 1 and optionally day 2, as described in Gilead patent US20220110943A1.
The compound’s solid forms are separately protected under US20220356182A1, filed April 2022, covering crystalline and amorphous polymorphs critical to the subcutaneous formulation’s stability and injectability. This layered IP strategy — method-of-use patents stacked atop compound and formulation patents — is characteristic of Gilead’s approach to long-acting antiretroviral protection, as documented across the patent record analysed by PatSnap.
A capsid inhibitor targets the protein shell (capsid) that encases the HIV genome. Unlike reverse transcriptase or integrase inhibitors, capsid inhibitors can interfere with multiple steps of the viral lifecycle simultaneously — nuclear import, reverse transcription, and assembly — contributing to the compound’s potency and durability at low dosing frequencies.
The PURPOSE clinical programme: from PURPOSE-1 to PURPOSE-4
The PURPOSE programme is Gilead’s multi-arm Phase 3 strategy to generate regulatory-grade evidence for lenacapavir PrEP across every major demographic group at elevated HIV risk. PURPOSE-1 enrolled cisgender women and adolescent girls in sub-Saharan Africa and delivered the signal that drove the entire programme forward: twice-yearly subcutaneous lenacapavir achieved zero HIV infections among participants, a result that set a new benchmark for prevention efficacy and prompted Gilead to accelerate the remaining trials.
PURPOSE-1, the first Phase 3 trial of lenacapavir PrEP, enrolled cisgender women and adolescent girls in sub-Saharan Africa and demonstrated zero HIV infections among participants receiving twice-yearly subcutaneous lenacapavir injections.
PURPOSE-2 extended the geographic and demographic scope, while PURPOSE-3 and PURPOSE-4 address the populations that PURPOSE-1 did not cover. PURPOSE-3 targets cisgender men who have sex with men and transgender individuals — populations that account for a substantial share of new HIV diagnoses globally, according to surveillance data published by WHO. PURPOSE-4 encompasses additional at-risk groups to complete the evidence package needed for broad-label regulatory submissions.
The strategic logic behind this trial architecture is straightforward: a single-population efficacy result, however strong, is insufficient for a broad regulatory label. By running parallel trials across diverse cohorts, Gilead is constructing the evidence base required to support submissions to the US FDA, the European Medicines Agency, and national regulatory authorities across high-burden regions. The patent record reinforces this ambition: WO2022079580A1, filed through WIPO in October 2021, establishes the prevention-use claim internationally, providing IP coverage that mirrors the geographic scope of the clinical programme.
“Biannual subcutaneous lenacapavir PrEP achieved zero HIV infections in PURPOSE-1 — a result that set a new benchmark for prevention efficacy and accelerated the entire PURPOSE programme.”
Track Gilead’s full lenacapavir patent family and PURPOSE trial pipeline in real time.
Explore lenacapavir data in PatSnap Eureka →Gilead’s lenacapavir patent portfolio: scope and strategy
PatSnap data identifies more than 24 patent publications from Gilead Sciences directly related to lenacapavir for treating or preventing HIV infection, filed across US and WIPO jurisdictions between October 2021 and November 2023. The portfolio divides into two functionally distinct clusters: method-of-use patents covering PrEP dosing regimens, and compound/formulation patents covering the capsid inhibitor molecule and its solid-state forms.
The method-of-use cluster is anchored by three core inventor teams. Guillaume Camus, Robert James Begley, and Joseph Hindman are named on the foundational PrEP dosing patents — including US20220110943A1, WO2022079580A1, WO2022261322A1, and the July 2023 “decreasing HIV transmission risk” family (WO2024015462A1, US20240041900A1, US20240041904A1, US20240041905A1, US20240033281A1). The November 2023 filing cluster (US20240238323A1, US20240238315A1, US20240156868A1, US20240350481A1, WO2024097810A1) represents the most recent expansion of that team’s method claims.
Gilead Sciences has filed more than 24 patent publications related to lenacapavir for treating or preventing HIV infection, spanning US and WIPO jurisdictions. Key inventors on the PrEP dosing method patents include Guillaume Camus, Robert James Begley, and Joseph Hindman.
The compound and formulation cluster is led by a separate team: Ming Zhong, Celia Pena Ruiz, Neeraj Patel, Zheng Wang, and John Parks. Their patents — including US20220168327A1, US20230165877A1, US20230174531A1, US20230183259A1, US20230357289A1, US20230365597A1, US20230382908A1, US20230416278A1, US11897884B2, US20240082291A1, US20240082293A1, WO2024039795A1 — protect the chemical entities themselves, including next-generation capsid inhibitor analogues that could extend Gilead’s franchise beyond lenacapavir’s current structure. This separation of inventor teams between method and compound patents is a deliberate strategy to maximise claim diversity and extend the effective period of IP protection.
Gilead’s lenacapavir portfolio layers method-of-use patents (biannual PrEP dosing, HIV transmission risk reduction) atop compound patents (capsid inhibitor molecules) and formulation patents (solid forms for subcutaneous injection). This three-tier structure creates overlapping exclusivity windows that extend beyond any single patent’s expiry.
Biannual dosing claims: how Gilead’s IP protects the PrEP regimen
The biannual subcutaneous dosing schedule is the commercial and clinical cornerstone of lenacapavir PrEP, and Gilead has constructed a dense set of patent claims around it. The foundational claim structure, first established in WO2022079580A1 and its US counterpart US20220110943A1, covers the specific sequence of oral loading dose on day 1 (optionally day 2) followed by subcutaneous injections every 26 weeks in HIV-negative individuals at risk for infection.
WO2022261322A1, filed June 2022, extends the claim scope to cover once-weekly and once-monthly administration in combination with other antiretroviral agents — a strategic broadening that captures potential combination PrEP regimens before competitors can establish prior art. The patent explicitly covers biannual administration of lenacapavir in combination with another antiretroviral agent to HIV-negative subjects at risk for HIV infection for pre-exposure prophylaxis, as stated in the abstract. This combination claim is significant because it anticipates the possibility that lenacapavir PrEP could eventually be co-administered with a second long-acting agent as part of a dual-drug prevention strategy.
The July 2023 filing cluster — WO2024015462A1 and its US national phase counterparts — reframes the same regimen under the claim language of “decreasing the risk of HIV transmission,” a subtle but strategically important variation. This alternative claim framing provides a separate patent family that can be asserted independently, even if the primary PrEP method claims are challenged or narrowed during prosecution. Such defensive claim diversification is a standard technique in pharmaceutical IP, and its presence in Gilead’s lenacapavir portfolio signals the company’s long-term commitment to protecting the twice-yearly injection schedule as the commercial anchor of the franchise. The PatSnap innovation intelligence platform provides full family mapping across all these filing clusters.
Map the full Gilead lenacapavir patent family tree — claims, jurisdictions, and prosecution status.
Analyse patents in PatSnap Eureka →What PURPOSE-3 and PURPOSE-4 readouts mean for the HIV prevention landscape
Positive PURPOSE-3 and PURPOSE-4 readouts would complete the clinical evidence package needed for Gilead to seek a broad-label approval for lenacapavir PrEP across all major at-risk populations. The regulatory and commercial implications extend well beyond Gilead itself. A twice-yearly injectable PrEP option with demonstrated efficacy across cisgender women, cisgender men who have sex with men, and transgender individuals would represent a fundamental shift in the HIV prevention toolkit — one that global health bodies including UNAIDS have identified as a priority for reaching the 95-95-95 targets.
From an IP perspective, the readouts will also determine the commercial window available to Gilead before generic or biosimilar competition can emerge. The patent families covering the biannual dosing method were filed in October 2021 and June 2022, giving nominal 20-year terms extending to 2041 and 2042 respectively — though patent term adjustments, supplementary protection certificates in Europe, and potential paediatric exclusivity extensions could further lengthen exclusivity in key markets. Competitors seeking to develop alternative long-acting PrEP agents will need to design around both the method-of-use claims and the capsid inhibitor compound patents, a challenge that the breadth of Gilead’s filing strategy has made considerably more difficult.
Gilead’s foundational lenacapavir PrEP method-of-use patents were filed in October 2021 and June 2022, giving nominal 20-year patent terms extending to approximately 2041 and 2042. Competitors developing alternative long-acting PrEP agents must design around both Gilead’s method-of-use claims and its capsid inhibitor compound patents.
The combination therapy patent WO2022261322A1 adds a further dimension: by claiming biannual lenacapavir in combination with other antiretrovirals, Gilead has pre-empted the most obvious competitive response — pairing a rival long-acting agent with lenacapavir to create a dual-drug PrEP regimen. Any company attempting to develop such a combination would need to either license Gilead’s combination claims or challenge their validity. This dynamic makes the PURPOSE-3 and PURPOSE-4 readouts not merely clinical milestones but pivotal events in the competitive IP landscape for next-generation HIV prevention.
For drug intelligence teams and IP professionals tracking this space, the November 2023 filing cluster (five publications from a single filing date) is a signal worth monitoring closely. It represents Gilead’s most recent expansion of method claims and may reflect internal data from the ongoing PURPOSE trials informing the scope of new claim language. Tracking prosecution outcomes on these applications — particularly claim allowances and office actions — will provide early intelligence on the strength of Gilead’s IP position as PURPOSE-3 and PURPOSE-4 data become public. The PatSnap pharmaceutical intelligence solution provides prosecution history tracking across all major jurisdictions.